abs410.txt	although	the	histone	methyltransferase	ezh2	and	its	product	h3k27me3	are	wellstudied	in	cancer		little	is	known	about	their	role	and	potential	as	therapeutictargets	in	endometriosis		we	have	previously	reported	that	endometriotic	lesionsare	characterized	by	global	enrichment	of	h3k27me3		therefore		we	aimed	to	(1)characterize	the	expression	levels	of	ezh2	in	endometriotic	tissues		(2)	assessh3k27me3	enrichment	in	candidate	genes	promoter	regions		and	(3)	determine	ifpharmacological	inhibition	of	ezh2	impacts	migration		proliferation		and	invasionof	endometriotic	cells		immunohistochemistry	of	an	endometriosis-focused	tissuemicroarray	was	used	to	assess	the	ezh2	protein	levels	in	tissues		chromatinimmunoprecipitation-qpcr	was	conducted	to	assess	enrichment	of	h3k27me3	incandidate	gene	promoter	regions	in	tissues		immunofluorescence	was	performed	toassess	the	effect	of	an	ezh2-specific	pharmacological	inhibitor	on	h3k27me3global	enrichment	in	cell	lines		to	measure	effects	of	the	inhibitor	inmigration		proliferation		and	invasion	in	vitro	we	used	scratch		brdu		andmatrigel	assays		respectively		endometriotic	lesions	had	significantly	higherezh2Î±	nuclear	immunostaining	levels	compared	to	eutopic	endometrium	from	patients(glands		stroma)	and	controls	(glands)		h3k27me3	was	enriched	within	promoterregions	of	candidate	genes	in	some	but	not	all	of	the	endometriotic	lesions	inhibition	of	ezh2	reduced	h3k27me3	levels	in	the	endometriotic	cellsspecifically		and	also	reduced	migration		proliferation	but	not	invasion	ofendometriotic	epithelial	cells	(12z)		these	findings	support	future	preclinicalstudies	to	determine	in	vivo	efficacy	of	ezh2	inhibitors	as	promising	nonhormonaltreatments	for	endometriosis		still	an	incurable	gynecological	disease	
